

**REMARKS/ARGUMENTS**

With this response, claims 1-25 are pending. In response to the present restriction requirement, Applicants elect to prosecute Group IV, claims 7-8, 11-12, and 22-23, drawn to a method of treating a bacterial infection in a subject, comprising administering a therapeutically effective amount of an anti-bacterial phage.

According to the Office Action the invention of Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the claims lack the same or corresponding special technical features for allegedly failing to make a contribution over the prior art. The Office Action alleges that the special technical feature is a host production cell.


Applicants traverse restriction of the claims. In particular, groups I-V are all directed to defined-dose therapeutic phage, methods of making the defined-dose phage, and methods of using the defined-dose phage. The Office Action does not include reasoning for the selection of a host bacterium as a special technical feature or for restriction of these claim groups. Therefore, Applicants respectfully traverse the rejection.

**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,



Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 206-467-9600  
Fax: 415-576-0300  
Attachments  
BLK:blk  
61427467 v1